Biocardia ( (BCDA) ) has released its Q3 earnings. Here is a breakdown of the information Biocardia presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
BioCardia, Inc., based in Sunnyvale, California, is a biotechnology company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, utilizing its proprietary biotherapeutic delivery platforms.
In the third quarter of 2025, BioCardia reported significant progress in its clinical trials and financial results. The company secured $6 million in financing to support its CardiAMP cell therapy and Helix Transendocardial Delivery Catheter initiatives, with ongoing trials and regulatory submissions in the pipeline.
Key highlights include the CardiAMP cell therapy for heart failure, which showed promising results in completed trials and is currently enrolling for a phase 3 trial. The company also reported positive outcomes from its CardiAMP therapy for chronic myocardial ischemia, with patients experiencing improved exercise tolerance and reduced angina episodes. Additionally, the CardiALLO allogeneic cell therapy is advancing with no adverse events reported in its phase 1/2 study.
Financially, BioCardia’s net loss decreased for the quarter compared to the previous year, attributed to reduced compensation expenses. The company ended the quarter with a cash balance of $5.3 million, providing financial runway into the second quarter of 2026.
Looking ahead, BioCardia is poised for transformative growth with anticipated regulatory consultations and submissions, ongoing clinical trials, and strategic funding efforts. The company remains committed to advancing its therapeutic platforms and achieving key milestones in the coming quarters.